This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Monday's Small-Cap Winners & Losers

The small-cap sector crawled beneath the struggling broad indices Monday despite surging names like XTL Biopharmaceuticals (XTLB - Get Report), which announced it began a phase IIb trial of Bicifadine for treatment of diabetic neuropathic (nervous-system-related) pain.

Shares of the Valley Cottage, N.Y., company were up 30.4% to $1.76.

InPlay Technologies (NPLA), based in Phoenix, climbed on word of a purchase-order renewal for its thiNcoder rotary-switch technology. The customer, a "leading supplier of products for the global sleep and respiratory markets," agreed to buy at least one million units through Duraswitch licensees over the next 18 months for a new line of positive-airway-pressure-therapy products. InPlay shares were leaping 15.2% to $1.74.

Elsewhere, management-services firm Versar (VSR - Get Report) bounced 2.8% after swinging to a fiscal fourth-quarter profit of $803,000, as well as posting a more-than-tripled full-year profit of $5.3 million, or 62 cents a share. Full-year sales soared 68.7% to $102.7 million. Shares of the Springfield, Va., company were trading at $8.94.

On the downside today, however, was Cardica (CRDC - Get Report), which slid 15.4% to $8.39 after A.G. Edwards cut the stock to sell from buy. The analyst said its shares spiked too high after last week's announcement of two pioneering closed-chest bypass surgeries using a Cardica device that automates the attachment of a blood vessel graft to a coronary artery during bypass surgery.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
CENT $9.46 -2.00%
CRDC $0.38 -11.00%
XTLB $2.22 0.87%
VSR $3.67 1.10%
AAPL $132.47 1.70%

Markets

DOW 18,038.17 -41.97 -0.23%
S&P 500 2,109.30 -8.39 -0.40%
NASDAQ 5,055.7860 -36.2990 -0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs